Non-clear cell renal cell carcinoma
Clinical trials for Non-clear cell renal cell carcinoma explained in plain language.
Never miss a new study
Get alerted when new Non-clear cell renal cell carcinoma trials appear
Sign up with your email to follow new studies for Non-clear cell renal cell carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo targets rare kidney cancer in early trial
Disease control OngoingThis study tests a combination of two drugs (fruquintinib and serplulimab) as the first treatment for people with a rare type of kidney cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors or slow the disease. About 39 adults will t…
Matched conditions: NON-CLEAR CELL RENAL CELL CARCINOMA
Phase 2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a drug combo outperform standard therapy for a rare kidney cancer?
Disease control OngoingThis phase 3 trial is testing whether a combination of the experimental drug XL092 and the immunotherapy nivolumab can help people with advanced non-clear cell kidney cancer live longer without their disease worsening. Participants have not received prior treatment for their adva…
Matched conditions: NON-CLEAR CELL RENAL CELL CARCINOMA
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New combo shows promise for rare kidney cancers
Disease control OngoingThis study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 participants will receive the drugs until their disease gets worse or side effects become too severe. The goal is …
Matched conditions: NON-CLEAR CELL RENAL CELL CARCINOMA
Phase 1/2 • Sponsor: Hao Zeng • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug cocktail aims to prevent kidney cancer recurrence in High-Risk patients
Disease control OngoingThis study tests whether combining two drugs—serplulimab and fruquintinib—can prevent kidney cancer from returning after surgery in people with a rare, aggressive type called non-clear cell renal cell carcinoma. About 40 adults at high risk of recurrence will receive both drugs f…
Matched conditions: NON-CLEAR CELL RENAL CELL CARCINOMA
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC